Related Experiment Video

Updated: Jul 26, 2025

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.1K

Treatment issues in recurrent Clostridioides difficile infections and the possible role of germinants

Noah Budi1, Nasia Safdar2, Warren E Rose1

  • 1School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA, 53705.

FEMS Microbes
|June 19, 2023
PubMed

Insights

Clostridioides difficile infections (CDI) often recur because treatments fail to eliminate resilient spores. New strategies combining antibiotics with germinants are needed to target GI spores and prevent recurrent CDI.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Gastroenterology

Background:

  • Clostridioides difficile is a leading cause of hospital-acquired infections and an urgent threat.
  • Pathogenic C. difficile causes inflammation, diarrhea, and pseudomembranous colitis, often leading to recurrent infections post-treatment.
  • Current treatments eliminate vegetative bacteria but not resilient spores, which resist antibiotics and cleaning.

Purpose of the Study:

  • To review C. difficile colonization, current treatments, and novel therapeutic strategies.
  • To emphasize the importance of targeting gastrointestinal spores to prevent recurrent C. difficile infections (CDI).
  • To explore germinant-antibiotic combinations as a potential treatment direction.

Main Methods:

  • Literature review focusing on C. difficile spore resistance and treatment limitations.
  • Analysis of current therapeutic approaches for C. difficile infections (CDI).
  • Exploration of emerging strategies for managing C. difficile spores in the GI tract.

Main Results:

  • Existing treatments for CDI are ineffective against C. difficile spores.
  • Antibiotic use can disrupt the microbiome, increasing vulnerability to recurrent CDI.
  • No current treatments specifically target GI spores during CDI antibiotic therapy.

Conclusions:

  • Effective management of C. difficile spores in the GI tract is crucial for advancing CDI treatment.
  • Germinant-antibiotic combinations represent a promising avenue for preventing recurrent CDI.
  • Targeting spore germination alongside antibiotic therapy could offer a solution to treatment failures.

Keywords:
Clostridioidescolonization resistancedifficilegerminationmicrobiomerecurrence

More Related Videos

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

38.9K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R2029106:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.6K

Related Concept Videos

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
164
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
202
Endospores and Sporulation01:20

Endospores and Sporulation

Endospores are specialized, dormant cells primarily formed by Gram-positive bacteria, including Bacillus and Clostridium, enabling survival under extreme environmental conditions. Due to their unique composition and formation process, these structures are highly resistant to physical and chemical insults, such as extreme heat, ultraviolet and ionizing radiation, desiccation, and toxic chemicals. Rare instances of endospore-like structures have also been observed in some Gram-negative bacteria,...
93
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
43
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
219